Last reviewed · How we verify
half-dose ticagrelor
Half-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events.
Half-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events. Used for Acute coronary syndrome (ACS), Secondary prevention of thrombotic cardiovascular events.
At a glance
| Generic name | half-dose ticagrelor |
|---|---|
| Sponsor | First Affiliated Hospital of Harbin Medical University |
| Drug class | P2Y12 receptor antagonist |
| Target | P2Y12 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist that blocks ADP-induced platelet activation more rapidly and potently than other P2Y12 inhibitors. The half-dose formulation reduces the standard therapeutic dose to potentially minimize bleeding risk while maintaining antiplatelet efficacy. This approach is being evaluated in clinical settings to optimize the benefit-risk profile in acute coronary syndrome and other thrombotic conditions.
Approved indications
- Acute coronary syndrome (ACS)
- Secondary prevention of thrombotic cardiovascular events
Common side effects
- Bleeding
- Bradycardia
- Dyspnea
- Ventricular pauses
Key clinical trials
- Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype (PHASE4)
- Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) (PHASE3)
- Clopidogrel And Ticagrelor in Healthy Subjects (PHASE3)
- Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI (PHASE4)
- Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD (PHASE4)
- Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- half-dose ticagrelor CI brief — competitive landscape report
- half-dose ticagrelor updates RSS · CI watch RSS
- First Affiliated Hospital of Harbin Medical University portfolio CI